Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ko Yamamoto

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
JACC. Asia|November 27, 2025
Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free StrategyTenjin Nishikura, Ko Yamamoto, Kohei Wakabayashi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 25, 2025
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trialTakenori Domei, Ko Yamamoto, Masahiro Natsuaki, et al.
JACC. Asia|December 2, 2024
Update on Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement in Asian PatientsKenichi Ishizu, Kazuki Kitano, Ko Yamamoto, et al.
The American Journal of Cardiology|July 8, 2023
Post-contrast Acute Kidney Injury After Emergent and Elective Percutaneous Coronary Intervention (from the CREDO-Kyoto PCI/CABG Registry Cohort 3)Kazuhisa Kaneda, Hiroki Shiomi, Mitsuru Abe, et al.
The American Journal of Cardiology|December 19, 2024
Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease and Chronic Kidney DiseaseKo Yamamoto, Hiroki Shiomi, Ryusuke Nishikawa, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 18, 2026
Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes - Prespecified Subgroup Analysis of the STOPDAPT-3 TrialKenji Kanenawa, Ko Yamamoto, Takenori Domei, et al.
The American Journal of Cardiology|July 30, 2023
The Impact of Mitral Regurgitation on Long-Term Outcomes in Acute Myocardial Infarction Undergoing Percutaneous Coronary InterventionYuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, et al.
The American Journal of Cardiology|August 16, 2022
Stroke Risk Stratification With the CHADS<sub>2</sub> Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary InterventionYuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, et al.
Circulation|November 23, 2023
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
JACC. Cardiovascular Interventions|January 4, 2023
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary InterventionKo Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
JACC. Asia|November 27, 2025
Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free StrategyTenjin Nishikura, Ko Yamamoto, Kohei Wakabayashi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 25, 2025
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trialTakenori Domei, Ko Yamamoto, Masahiro Natsuaki, et al.
JACC. Asia|December 2, 2024
Update on Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement in Asian PatientsKenichi Ishizu, Kazuki Kitano, Ko Yamamoto, et al.
The American Journal of Cardiology|July 8, 2023
Post-contrast Acute Kidney Injury After Emergent and Elective Percutaneous Coronary Intervention (from the CREDO-Kyoto PCI/CABG Registry Cohort 3)Kazuhisa Kaneda, Hiroki Shiomi, Mitsuru Abe, et al.
The American Journal of Cardiology|December 19, 2024
Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease and Chronic Kidney DiseaseKo Yamamoto, Hiroki Shiomi, Ryusuke Nishikawa, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 18, 2026
Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes - Prespecified Subgroup Analysis of the STOPDAPT-3 TrialKenji Kanenawa, Ko Yamamoto, Takenori Domei, et al.
The American Journal of Cardiology|July 30, 2023
The Impact of Mitral Regurgitation on Long-Term Outcomes in Acute Myocardial Infarction Undergoing Percutaneous Coronary InterventionYuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, et al.
The American Journal of Cardiology|August 16, 2022
Stroke Risk Stratification With the CHADS<sub>2</sub> Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary InterventionYuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, et al.
Circulation|November 23, 2023
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
JACC. Cardiovascular Interventions|January 4, 2023
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary InterventionKo Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Pageof 10